ReviewStroke and vascular neurology2020
Updates in arteriovenous malformation management: the post-ARUBA era.
Review in Stroke and vascular neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Risk of intracranial hemorrhage in brain arteriovenous malformations: a systematic review and meta-analysis.Journal of neurology · 2024Pooled it
- A systematic review and meta-analysis of surgeries performed for cerebral cavernous malformation-related epilepsy in pediatric patients.Frontiers in pediatrics · 2022Pooled it
- Controlled arterial hypotension during resection of cerebral arteriovenous malformations.BMC neurology · 2021Trial
- Obliteration Rate of Arteriovenous Malformation by Radiosurgery.The Malaysian journal of medical sciences : MJMS · 2025Article
- Interventional Treatment vs Conservative Management of Unruptured Brain Arteriovenous Malformations.JAMA network open · 2025Observational
- Article
- Surgical Results with Low-Grade Arteriovenous Malformations : A Single Center 14-Year Experience.Journal of Korean Neurosurgical Society · 2024Article
- Trends in AVM-Associated Intracranial Hemorrhage in the United States, 2000-2019.JAMA neurology · 2024Article
- Commentary: Will dexamethasone ever have a role in the management of chronic subdural hematomas?Brain and behavior · 2024Article
- Multi-Stage Treatment for Spetzler-Martin Grades III, IV, and V Arteriovenous Malformations: Preoperative Embolization and Microsurgical Resection in a Consecutive Series of 250 Patients.Journal of clinical medicine · 2023Article
- Multimodality treatment for brain arteriovenous malformation in Mainland China: design, rationale, and baseline patient characteristics of a nationwide multicenter prospective registry.Chinese neurosurgical journal · 2022Article
- Venous Rupture Following Transcatheter Arterial Embolization for Inferior Mesenteric Type II Arteriovenous Malformation.Interventional radiology (Higashimatsuyama-shi (Japan) · 2022Article
- Untangling the Modern Treatment Paradigm for Unruptured Brain Arteriovenous Malformations.Journal of personalized medicine · 2022Review
- Grading scale based on arcuate fasciculus segmentation to predict postoperative language outcomes of brain arteriovenous malformations.Stroke and vascular neurology · 2022Article
- Vessel Wall Magnetic Resonance Imaging in Cerebrovascular Diseases.Diagnostics (Basel, Switzerland) · 2022Review
- Fatal ruptured occult arteriovenous malformation in a young adult: An autopsy case report.Surgical neurology international · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain arteriovenous malformations (AVMs) are complex and heterogeneous lesions that can rupture, causing significant morbidity and mortality. While ruptured lesions are usually treated, the management of unruptured AVMs remains unclear. A Randomized trial of Unruptured Brain Arteriovenous Malformations (ARUBA) was the first trial conducted to compare the effects of medical and interventional therapy. Although it concluded that medical therapy was superior in preventing stroke and death over a follow-up period of 33 months, the findings were met with intense criticism regarding several aspects of study design, progression, and analysis/conclusion. Namely, the increased use of stand-alone embolisation relative to microsurgery in a cohort with predominantly low-grade lesions combined with a short follow-up period amplified treatment risk. Subsequently, several observational studies were conducted on ARUBA-eligible patients to investigate the safety and efficacy of microsurgery, radiosurgery, and endovascular embolisation over longer follow-up periods. These reports showed that favourable safety profiles and cure rates can be achieved with appropriate patient selection and judicious use of different treatment modalities in multidisciplinary centres. Since large prospective randomised trials on AVMs may not be feasible, it is important to make use of practice-based data beyond the flawed ARUBA study to optimise patients' lifetime outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.